Ocular Therapeutix announced FDA alignment to submit a New Drug Application (NDA) for AXPAXLI, a treatment for wet age-related macular degeneration (wet AMD), in the fourth quarter of 2026. The submission will be based on strong efficacy and safety data from the SOL-1 trial and interim safety data from the SOL-R trial. The company has adjusted the SOL-R trial to focus on long-term superiority endpoints, with topline results expected in early 2028. Additionally, Ocular is streamlining its diabetic retinopathy program to prioritize the HELIOS-3 trial, targeting a once-yearly dosing regimen. If approved, AXPAXLI could offer a best-in-class treatment option with reduced treatment burden for patients, potentially launching in 2027.
The global medical alert systems market is projected to grow from $10.5 billion in 2025 to $23.5 billion by 2035, at a CAGR of 8.45%. Growth is fueled by an increasing elderly population preferring to age in place and advances in mobile and standalon...
The global helium market, valued at $5.03 billion in 2025, is projected to grow to $8.59 billion by 2035 with a CAGR of 5.47%. Growth is fueled by rising demand in healthcare for MRI superconducting magnet cooling and expanding semiconductor manufact...
Defiance ETFs has launched the first Memory UCITS ETF (DRAM) in Europe, focusing on companies involved in memory semiconductors and data storage systems. This ETF offers European investors access to the growing memory sector driven by AI, cloud compu...
Defiance ETFs has introduced the Defiance Memory UCITS ETF (DRAM), the first memory-focused ETF in Europe, listed on Xetra and Borsa Italiana, with plans for London Stock Exchange. This ETF targets companies involved in memory semiconductors and data...
Defiance ETFs has introduced the Defiance Memory UCITS ETF (DRAM), the first European ETF focused on semiconductor memory and data storage companies. This ETF provides European investors exposure to a sector driven by rising demand from AI, cloud com...
